Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.74 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.53 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.52 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8295108 | 1.00 | NOD1 (0.74) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18573779 | 1.00 | NOD1 (0.74) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL8295114 | 1.00 | NOD1 (0.74) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL13963977 | 1.00 | NOD1 (0.74) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL23601770 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18560506 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL14478728 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL14725995 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL18783045 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT | |
| SCHEMBL71687 | 0.97 | NOD1 (0.69) | NOD1PLA2G2CSLC6A5PLA2G10GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604555-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2020-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604555-B2 | GIP derivatives and uses thereof | GIPR, GLP1R, GPR119 | NOD1 2846/4885PLA2G2C 585/4885SLC6A5 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.